3-Fluoro-Piperidinium

3-Fluoro-Piperidinium

SCHEMBL234401

F[C@H]1CCCNC1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
3-Fluoro-Piperidinium SCHEMBL26108 1.00
3-Fluoro-Piperidinium SCHEMBL12071659 1.00
3-Fluoro-Piperidinium SCHEMBL4931214 0.97
3-Fluoro-Piperidinium SCHEMBL16934912 0.97
3-Fluoro-Piperidinium SCHEMBL25959 0.97
SCHEMBL31756018 0.92
SCHEMBL31756091 0.92
SCHEMBL16903355 0.92
Hydrochloric Acid SCHEMBL21200458 0.89
Bromide SCHEMBL30604105 0.89

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116888-A1 CYCLIN-DEPENDENT KINASE INHIBITORS NOVARTIS AG (CH) 2026-04-30 US disclosed
US-20260028336-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-01-29 US disclosed
EP-4631948-A1 NOVEL TRICYCLIC COMPOUND AS KRAS G12D INHIBITOR, AND USE THEREOF SK Biopharmaceuticals Co., Ltd. (KR) 2025-10-15 EP disclosed
EP-4558501-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2025-05-28 EP disclosed
CN-120025279-A Compounds capable of modulating endoplasmic reticulum aminopeptidase 1 格雷沃尔夫治疗有限公司 2025-05-23 CN disclosed
US-20240400587-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS INC (US) 2024-12-05 US disclosed
US-20240360118-A1 Bicyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2024-10-31 US disclosed
EP-4430052-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF Nurix Therapeutics, Inc. (US) 2024-09-18 EP disclosed
US-12091426-B2 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof NURIX THERAPEUTICS, INC. (US) 2024-09-17 US disclosed
US-12071425-B2 Phenoxy-pyridyl-pyrimidine compounds and methods of use GENENTECH, INC. (US) 2024-08-27 US disclosed
US-8372841-B2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme ABBOTT LABORATORIES (US) 2013-02-12 US disclosed
US-20120004206-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBVIE INC. 2012-01-05 US disclosed
EP-2345640-A1 Adamantyl- acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme Abbott Laboratories (US) 2011-07-20 EP disclosed
WO-2011026911-A1 BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2011-03-10 WO disclosed
US-7880001-B2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme ABBOTT LABORATORIES (US) 2011-02-01 US disclosed
US-20100222316-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2010-09-02 US disclosed
US-20090192141-A1 METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2009-07-30 US disclosed
EP-1751108-A1 ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2007-02-14 EP disclosed
US-20050277647-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme ABBVIE INC. 2005-12-15 US disclosed
WO-2005108368-A1 ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2005-11-17 WO disclosed